Australia's most trusted
source of pharma news
Thursday, 30 July 2026
Posted 30 July 2026 AM
CSL has announced Phase 3 trials in its efforts to increase the yield of its plasma facilities, with an eye on regulatory approvals.
The next generation process to produce immunoglobulin, Horizon 2, will enter clinical trials to confirm efficacy and safety starting mid-2027. The patented technology enables significantly greater production of immunoglobulin from the same base amount of plasma.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.